A Phase I Clinical Trial for JY028 (single-dose; vitreous injection) on Safety , tolerability, pharmacokinetics (PK) and pharmacodynamics for Patients with wet Age-related macular degeneration

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022369

Enrollment

Unknown

Registered

2019-04-08

Start date

2019-12-30

Completion date

Unknown

Last updated

2019-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration

Interventions

1:intravitreal injection JY028 0.625mg

2:intravitreal injection JY028 1.25mg

3:intravitreal injection JY028 2mg

4:intravitreal injection JY028 2.5mg

Eligibility

Sex/Gender

All

Age

50 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients voluntarily participated and signed the informed consent; Male or female, aged 50-80 years; To be diagnosed as wet age related macular degeneration.

Exclusion criteria

Exclusion criteria: Choroidal polypoid angiopathy (PCV); There are other obvious ocular diseases/conditions other than AMD (such as diabetic retinopathy, cataract, eyelid Abnormalities, uncontrolled glaucoma, eye active inflammation, etc.); Fluorescein sodium allergy; Pregnant or lactating women and those who cannot take contraceptive measures; The candidate was judged unfit by the investigator.

Design outcomes

Secondary

Measure	Time frame
pharmacokinetics;	—

Countries

China

Contacts

Public ContactZhao Xiuli

zhouqin@east-bt.com+86 010-58268486-8008

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026